DANIEL FEENEY: Open Payments
NPI 1326012949 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,326 in 67 payments from 13 companies in 2025. Trend: 2023 $1,463 · 2024 $968 · 2025 $1,326
Food & beverage: $1,326
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 19 | $331 |
| ABBVIE INC. | 10 | $193 |
| Teva Pharmaceuticals USA, Inc. | 5 | $123 |
| Otsuka America Pharmaceutical, Inc. | 5 | $109 |
| Janssen Pharmaceuticals, Inc | 5 | $100 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $98 |
| Lundbeck LLC | 4 | $83 |
| Alkermes, Inc. | 4 | $78 |
| LivaNova USA, Inc. | 2 | $76 |
| Collegium Pharmaceutical, Inc. | 3 | $46 |
Products named: INGREZZA, VRAYLAR, REXULTI, INVEGA SUSTENNA, CAPLYTA, ARISTADA, AUSTEDO XR, VNS THERAPY SYMMETRY MODEL 8103 GENERATOR.
Industry payments across LA — which companies pay providers there.
